Tekmira gets injunction against AlCana, as date for Alnylam trade secrets trial is set
This article was originally published in Scrip
Executive Summary
Tekmira Pharmaceuticals, the Vancouver, BC-based developer of RNA interference (RNAi) therapeutics, said the Supreme Court of British Columbia has granted its application for an injunction against AlCana Technologies, that orders confidential documents and materials be returned to Tekmira and prohibits the use of the company’s confidential information.